BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9609217)

  • 1. Low molecular weight heparin decreases proximal and distal deep venous thrombosis following total knee arthroplasty. A meta-analysis of randomized trials.
    Howard AW; Aaron SD
    Thromb Haemost; 1998 May; 79(5):902-6. PubMed ID: 9609217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Low-molecular-weight heparin for preventing deep-vein thrombosis after total joint arthroplasty].
    Yang G; Lu H; Gao J; Kou B; Yuan Y; Xu B
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):25-7. PubMed ID: 11831980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
    Brookenthal KR; Freedman KB; Lotke PA; Fitzgerald RH; Lonner JH
    J Arthroplasty; 2001 Apr; 16(3):293-300. PubMed ID: 11307125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients: a meta-analysis of randomized controlled trials.
    Wein L; Wein S; Haas SJ; Shaw J; Krum H
    Arch Intern Med; 2007 Jul; 167(14):1476-86. PubMed ID: 17646601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of low molecular weight heparin in total knee arthroplasty.
    Iobst CA; Friedman RJ
    Am J Knee Surg; 1999; 12(1):55-60. PubMed ID: 10050695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melagatran and ximelagatran: new drug. No real simplification of anticoagulant therapy.
    Prescrire Int; 2005 Aug; 14(78):127-32. PubMed ID: 16106594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis].
    Nielsen JD; Landorph A
    Ugeskr Laeger; 1994 Oct; 156(40):5844-9. PubMed ID: 7985276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
    Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
    Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for low-molecular-weight heparin prophylaxis after total knee arthroplasty.
    Colwell CW; Hardwick ME
    Clin Orthop Relat Res; 2006 Nov; 452():181-5. PubMed ID: 17016231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses.
    Koch A; Bouges S; Ziegler S; Dinkel H; Daures JP; Victor N
    Br J Surg; 1997 Jun; 84(6):750-9. PubMed ID: 9189079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical risk factors for deep vein thrombosis after total hip and knee arthroplasty].
    Guan ZP; Lü HS; Chen YZ; Song YN; Qin XL; Jiang J
    Zhonghua Wai Ke Za Zhi; 2005 Oct; 43(20):1317-20. PubMed ID: 16271243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, natural history and risk factors of deep vein thrombosis in elective knee arthroscopy.
    Delis KT; Hunt N; Strachan RK; Nicolaides AN
    Thromb Haemost; 2001 Sep; 86(3):817-21. PubMed ID: 11583313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
    Själander A; Jansson JH; Bergqvist D; Eriksson H; Carlberg B; Svensson P
    J Intern Med; 2008 Jan; 263(1):52-60. PubMed ID: 18088252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement.
    O'Brien BJ; Anderson DR; Goeree R
    CMAJ; 1994 Apr; 150(7):1083-90. PubMed ID: 8137188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of postoperative thrombosis with low-molecular-weight heparins].
    Jørgensen LN; Wille-Jørgensen PA; Hauch O
    Ugeskr Laeger; 1994 Sep; 156(39):5667-72. PubMed ID: 7985248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.